221 related articles for article (PubMed ID: 37773300)
1. Evolution of predictive risk factor analysis for chemotherapy-related toxicity.
Hertz DL; Lustberg MB; Sonis S
Support Care Cancer; 2023 Sep; 31(10):601. PubMed ID: 37773300
[TBL] [Abstract][Full Text] [Related]
2. Status of Immune Oncology: Challenges and Opportunities.
Cesano A; Marincola FM; Thurin M
Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145
[TBL] [Abstract][Full Text] [Related]
3. Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology.
Chen EI; Crew KD; Trivedi M; Awad D; Maurer M; Kalinsky K; Koller A; Patel P; Kim Kim J; Hershman DL
PLoS One; 2015; 10(12):e0145816. PubMed ID: 26710119
[TBL] [Abstract][Full Text] [Related]
4. Cancer biomarker discovery and translation: proteomics and beyond.
Hristova VA; Chan DW
Expert Rev Proteomics; 2019 Feb; 16(2):93-103. PubMed ID: 30556752
[TBL] [Abstract][Full Text] [Related]
5. Innovative methods for biomarker discovery in the evaluation and development of cancer precision therapies.
Umelo IA; Costanza B; Castronovo V
Cancer Metastasis Rev; 2018 Mar; 37(1):125-145. PubMed ID: 29392535
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics: Driving Personalized Medicine.
Sadee W; Wang D; Hartmann K; Toland AE
Pharmacol Rev; 2023 Jul; 75(4):789-814. PubMed ID: 36927888
[TBL] [Abstract][Full Text] [Related]
7. Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships.
Hertz DL
Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):227-239. PubMed ID: 33401943
[No Abstract] [Full Text] [Related]
8. Power of proteomics and progress in precision medicine - 13th central and eastern European proteomic conference (CEEPC), Ustroń, Poland.
Gadher SJ; Widlak P; Kovarova H
Expert Rev Proteomics; 2020 May; 17(5):335-340. PubMed ID: 32510255
[TBL] [Abstract][Full Text] [Related]
9. Prediction of individual response to anticancer therapy: historical and future perspectives.
Unger FT; Witte I; David KA
Cell Mol Life Sci; 2015 Feb; 72(4):729-57. PubMed ID: 25387856
[TBL] [Abstract][Full Text] [Related]
10. Multi-omics strategies for personalized and predictive medicine: past, current, and future translational opportunities.
Ahmed Z
Emerg Top Life Sci; 2022 Apr; 6(2):215-225. PubMed ID: 35234253
[TBL] [Abstract][Full Text] [Related]
11. Germline Genetics in Immuno-oncology: From Genome-Wide to Targeted Biomarker Strategies.
Kirchhoff T; Ferguson R
Methods Mol Biol; 2020; 2055():93-117. PubMed ID: 31502148
[TBL] [Abstract][Full Text] [Related]
12. Identification of prognostic and predictive biomarkers in high-dimensional data with PPLasso.
Zhu W; Lévy-Leduc C; Ternès N
BMC Bioinformatics; 2023 Jan; 24(1):25. PubMed ID: 36690931
[TBL] [Abstract][Full Text] [Related]
13. Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification.
Fu S; Liu X; Luo M; Xie K; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2017 Apr; 14(4):351-362. PubMed ID: 28276747
[TBL] [Abstract][Full Text] [Related]
14. Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation.
Alymani NA; Smith MD; Williams DJ; Petty RD
Eur J Cancer; 2010 Mar; 46(5):869-79. PubMed ID: 20138504
[TBL] [Abstract][Full Text] [Related]
15. Mass spectrometry based proteomics and metabolomics in personalized oncology.
Kowalczyk T; Ciborowski M; Kisluk J; Kretowski A; Barbas C
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165690. PubMed ID: 31962175
[TBL] [Abstract][Full Text] [Related]
16. Beyond the limitation of targeted therapy: Improve the application of targeted drugs combining genomic data with machine learning.
Miao R; Chen HH; Dang Q; Xia LY; Yang ZY; He MF; Hao ZF; Liang Y
Pharmacol Res; 2020 Sep; 159():104932. PubMed ID: 32473309
[TBL] [Abstract][Full Text] [Related]
17. Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential.
Tuñón J; Barbas C; Blanco-Colio L; Burillo E; Lorenzo Ó; Martín-Ventura JL; Más S; Rupérez FJ; Egido J
Expert Rev Proteomics; 2016 Sep; 13(9):857-71. PubMed ID: 27459711
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic Predictors of Response.
Hertz DL; Rae JM
Adv Exp Med Biol; 2016; 882():191-215. PubMed ID: 26987536
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomic biomarkers for personalized cancer treatment.
Rodríguez-Antona C; Taron M
J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
